David Requena
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
-
- vaccines and immunoinformatics approaches 5
- Developmental Biology and Gene Regulation 4
- RNA Research and Splicing 3
- Genomics and Chromatin Dynamics 3
- Ubiquitin and proteasome pathways 3
-
- Tuberculosis Research and Epidemiology 4
- Co-authors
- David B. Solit (1 shared paper)Sviatoslav M. Kendall (1 shared paper)Ahmet Zehir (1 shared paper)James M. Carroll (1 shared paper)Nadeem Riaz (1 shared paper)Benjamin D. Greenbaum (1 shared paper)Timothy A. Chan (1 shared paper)Naiyer A. Rizvi (1 shared paper)
- Journals
- PLoS ONE (4 papers)Frontiers in Immunology (3 papers)BMC Genomics (2 papers)Molecular Therapy (1 paper)Molecular and Cellular Biology (1 paper)
- Partner nations
- United StatesPeruSpain
In The Last Decade
David Requena
34 papers receiving 1.2k citations
David Requena's Hit Papers
Peers
Comparison fields: 5 of 112
- Oncology 623
- Immunology 427
- Cancer Research 221
- Hepatology 73
- Pulmonary and Respiratory Medicine 198
Countries citing papers authored by David Requena
This map shows the geographic impact of David Requena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Requena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Requena more than expected).
Fields of papers citing papers by David Requena
This network shows the impact of papers produced by David Requena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Requena. The network helps show where David Requena may publish in the future.
Co-authors
The 25 scholars most cited alongside David Requena, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 738 |
| 2 | 2017 | 114 | |
| 3 | 2020 | 40 | |
| 4 | 2014 | 36 | |
| 5 | 2017 | 26 | |
| 6 | 2015 | 25 | |
| 7 | 2020 | 24 | |
| 8 | 2017 | 23 | |
| 9 | 2021 | 22 | |
| 10 | 2016 | 21 | |
| 11 | 2022 | 18 | |
| 12 | 2015 | 17 | |
| 13 | 2017 | 17 | |
| 14 | 2015 | 16 | |
| 15 | 2017 | 15 | |
| 16 | 2013 | 15 | |
| 17 | 2015 | 13 | |
| 18 | 2013 | 11 | |
| 19 | 2020 | 11 | |
| 20 | 2018 | 10 |
About David Requena
David Requena is a scholar working on Molecular Biology, Infectious Diseases, Immunology, Epidemiology and Plant Science, having authored 35 papers that have together received 1.3k indexed citations. Recurring topics across this work include vaccines and immunoinformatics approaches (5 papers), Tuberculosis Research and Epidemiology (4 papers), Developmental Biology and Gene Regulation (4 papers), RNA Research and Splicing (3 papers), Genomics and Chromatin Dynamics (3 papers), Ubiquitin and proteasome pathways (3 papers), Health Literacy and Information Accessibility (2 papers) and Animal Virus Infections Studies (2 papers). The work is most often cited by research in Oncology (623 citations), Immunology (427 citations), Cancer Research (221 citations), Hepatology (73 citations) and Pulmonary and Respiratory Medicine (198 citations). David Requena has collaborated with scholars based in United States, Peru and Spain. Frequent co-authors include David B. Solit, Sviatoslav M. Kendall, Ahmet Zehir, James M. Carroll, Nadeem Riaz, Benjamin D. Greenbaum, Timothy A. Chan, Naiyer A. Rizvi, Robert Samstein and Vladimir Makarov. Their work appears in journals such as PLoS ONE, Frontiers in Immunology, BMC Genomics, Molecular Therapy and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.